Dogs Can Be Successfully Trained to Alert to Hypoglycemia Samples from Patients with Type 1 Diabetes
Dana S Hardin1, Wesley Anderson2, Jennifer Cattet3
1Eli Lilly, Corp 225 S. Delaware, Indianapolis, USA. hardin_dana_sue@lilly.com.
Summary
Diabetes alert dogs (DADs) can be trained to detect hypoglycemia in people with type 1 diabetes. These dogs show high sensitivity and specificity in identifying low blood sugar through scent alone, offering a potential aid for those with hypoglycemia unawareness.
Area of Science:
- Endocrinology
- Animal Behavior
- Biomedical Science
Background:
- Hypoglycemia is a common, dangerous side effect of insulin therapy for type 1 diabetes (T1D).
- Hypoglycemia unawareness in T1D patients increases risks of severe morbidity and mortality.
- Diabetes alert dogs (DADs) offer a novel approach to assist individuals with T1D experiencing hypoglycemia unawareness.
Purpose of the Study:
- To evaluate the sensitivity and specificity of trained DADs in detecting hypoglycemia.
- To refine the assessment of DADs' ability to identify hypoglycemia, minimizing trainer bias.
Main Methods:
- Six dogs with 6 months of positive reinforcement training for hypoglycemia detection were evaluated.
- Perspiration samples from hypoglycemic and normoglycemic individuals were used in a scent detection test.
- Dogs alerted to the scent of hypoglycemia by interacting with a specific container; results were videotaped and analyzed.
Main Results:
- All dogs demonstrated statistically significant sensitivity (50.0%-87.5%) in detecting hypoglycemia samples, far exceeding random chance (14%).
- Dog specificity in identifying non-hypoglycemic samples ranged from 89.6% to 97.9%.
Conclusions:
- Trained diabetes alert dogs can effectively detect hypoglycemia using olfactory cues in an in vitro setting.
- DADs show promising potential as a non-invasive tool to assist individuals with T1D and hypoglycemia unawareness.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
01:06Oral Hypoglycemic Agents: Glinides
957
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
957
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.8K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.8K
01:14SBAR II: Application of SBAR
6.8K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.8K